From: Endpoints News
By: Beth Snyder Bulik
Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a laundry list of ongoing woes including insurance reimbursement uncertainty, dismal initial sales, a label flipflop, FDA advisory committee members resigning and outspoken researchers and public officials who continue to question the drug’s approval
So what to do about Aduhelm’s image? Not much for the neurologists beyond their clinical practice and personal interactions, however Biogen could potentially tackle it. Spherix Global Insights recently offered suggestions based on its interviews with neurologists that might help uptake…(read more)
